Abstract Aim of study. To describe the emergence of dengue 3 virus in Côte d'Ivoire during a yellow fever outbreak which occurred in 2008. Materials and methods. Sera from suspected cases of yellow fever as well as contacts of yellow fever confirmed cases and imported dengue fever cases were tested for immunoglobulin M (IgM) antiyellow fever virus and anti-dengue virus (for IgM antibodies to yellow fever and dengue viruses) and by a specific real time RT-PCR (BioRad) for yellow fever virus and dengue virus viral RNA detection. Results. Of the 511 sera from suspected cases of yellow fever tested, 21 (4.1%) were confirmed positive for yellow fever virus antibody, while 33 (7.6%) of the 432 sera tested were positive for dengue virus antibody. Thirteen viremic subjects, one for yellow fever virus and 12 for dengue 3 virus, were detected by RT-PCR. The majority of the confirmed cases of yellow fever (85%) and dengue 3 fever (93%) were adults, and resided in the city of Abidjan and its regions. Conclusion. These results indicate the existence of transmission foci of these arboviruses diseases in Côte d'Ivoire and the essential contribution of molecular tests for their diagnosis.
Introduction
Yellow fever and dengue are two arboviruses diseases plaguing in the tropical zones: dengue in Asia, Africa, Latin America, and the Caribbean, yellow fever in Latin America and Africa only. The responsible viruses from the family of Flaviviridae (genus Flavivirus) are transmitted by bloodsucking arthropods Aedes [10] . In the yellow fever zone of Africa, where 33 countries are exposed, the disease is spread in both the endemic and epidemic forms, with 508 million people affected. In South America, there are 11 countries that are concerned. Dengue is the foremost human arboviral infection, because 2.5 billion people are exposed with 50 to 100 million cases occurring causing 30,000 deaths annually. It is an economic scourge in the affected areas [19] . According to Gubler et al. (1986) , dengue is the cause of major epidemics in Asia. It exists today throughout the tropics, especially in Asia and South America where dengue fever is caused by four types of virus (serotypes 1, 2, 3, and 4). In Africa all the 4 serotypes of dengue virus serotypes were reported but serotypes 1 and 2 are predominant; however, the emergence of dengue 3 is new in Africa [11] . Dengue occurs in two clinical forms: classic dengue fever characterized by fever with a macular rash and lymphadenopathy sometimes, and dengue hemorrhagic fever, a severe form which has been described in Southeast Asia and the Caribbean [10] . In Côte d'Ivoire, Cordellier et al. (1983) reported the circulation of dengue (serotypes 1 and 2) virus in the vector Aedes aegypti and during human seroepidemiological studies in rural and urban areas [4] .
During virological investigations of yellow fever suspected cases in the second quarter of 2008, some sera were positive for dengue IgM antibodies in tests performed at the World Health Organization (WHO) Collaborating Reference Centre for Research on Arboviruses (CRORA), Pasteur Institute of Dakar (IPD). At the same time, dengue 3 imported cases from Côte d'Ivoire were reported in France and Japan [5, 19] , motivating collaborative studies organized by WHO, CRORA and the national reference center for arbovirus (CNR Arbovirus) of the Pasteur Institute of Paris (IPP). The main objective was to transfer the technology for dengue virus diagnosis and typing to the Pasteur Institute of Côte d'Ivoire (IPCI) and the national reference center for arbovirus and hemorrhagic fever viruses (CNR-AVHF). This report of these studies describe the emergence of dengue following the outbreak of an epidemic of yellow fever in 2008 in Côte d'Ivoire.
Materials and methods

Sampling
The sera samples tested come from two sources: (i) 511 sera of epidemiological surveillance of hemorrhagic fevers and (ii) 185 sera obtained from contacts of yellow fever and dengue confirmed cases.
The sample size has not been determined by a statistical method; this work consisted of an assessment of the results of the active epidemiological surveillance. All yellow fever suspected cases of the period have been included. Suspected cases are notified to the district level by the health workers who collected venous blood samples from each suspected case. From the district, an investigation form previously developed by the national service of epidemiological surveillance according to WHO guidelines was fulfilled; the blood sample and the form were sent to the arboviruses and hemorrhagic fevers national reference laboratory at the Pasteur institute of Côte d'Ivoire in Abidjan. The forms provided socio-demographic data, clinical symptoms, and immunization histories Moreover, all yellow fever and dengue confirmed cases have been investigated (epidemiological details and yellow fever immunization status, a venous blood sample from each case and contacts).
Between 1 January to 31 December 2008, during an active epidemiological surveillance of viral hemorrhagic fevers in 78 health districts of Côte d'Ivoire, 511 venous blood samples were collected from yellow fever suspected cases. YF case definition was according to WHO [6] .
Blood samples were also collected from contacts of yellow fever and dengue confirmed cases. Sera were separated from clotted whole blood samples by centrifugation at 3000 rpm, and used for virological confirmatory testing. Epidemiological details and yellow fever immunization status were obtained from each case and contact on a standard form including socio-demographic data, clinical symptoms and date of onset, date of the collection of samples, and so on. All sera were tested at the CNR-AVHF of IPCI.
From the 511 sera tested all for yellow fever, a first batch of 250 sera drawn at random without defined criteria among sera were found negative for IgM anti-yellow fever virus to be tested for IgM anti-dengue virus and a second batch of 182 early sera obtained within 7 days of the date of onset to be tested for viral RNA detection of by specific real time RT-PCR.
The 185 sera from contacts of confirmed cases of both diseases were tested for IgM anti-yellow fever virus and IgM anti-dengue virus.
Methods
Serological tests
Yellow fever IgM antibodies detection was performed by immunocapture assay on all the suspected cases sera and contact subjects according to WHO recommendations using the ELISA technique developed by the Centers for Disease Control (CDC) [6] .
All sera found positive were referred to CRORA for confirmatory testing and differential diagnosis by IgM against other arboviruses detection (dengue 2 virus, Chikungunya virus fever, virus of Rift Valley fever, virus of Crimean-Congo hemorrhagic fever, and West Nile virus). A double detection of specific IgM anti-dengue virus and IgM anti-yellow fever virus, based on the immunosorbent assay (ELISA) as described by Lhuillier and Sarthou [15] and performed on the same microplate (differential test) was transferred.
Molecular tests
Dengue and yellow fever virus ARN detection was performed on early samples obtained within 7 days of the date of onset of symptoms.
The whole RNA was extracted and purified using Qiaamp Viral RNA mini-kit (Qiagen) according to the manufacturer's guidelines. The detection of viral genomes was conducted by RT-PCR in real time using primers and probes described by Lanciotti et al. [14] . Thermal cycles of amplification were used on MiniOpticon 3 (Bio-Rad, France) according to Warrilow et al. [18] . The analysis of the amplification curves was performed by the Opticon3b software (Biorad, France).
Statistical analysis
For data analysis, the Epi/Info 6.2 software (CDC) was used and the Chi-square test (χ 2 ) was used for statistical comparison at alpha 0.05.
Results
Serology-anti-yellow fever virus and anti-dengue virus
Sera from surveillance system
Yellow fever antibodies Eighteen (3.5%) of 511 sera were positive for anti-yellow fever virus IgM antibody and five were equivocal (delta OD between 0.2 and 0.3). CRORA confirmed 17 of the 18 positive cases, one IgM positive serum from hemolyzed blood was not analyzed ( Table 1) . Two of the five equivocal sera were confirmed, while three were negative.
Dengue antibodies
Of the 250 sera which were initially negative for yellow fever IgM antibody and retested in double detection for both yellow fever and dengue IgM antibodies, 34 were positive for IgM: three specific for YF virus IgM antibody, 22 specific for DEN virus IgM antibody, and 9 positive for both YF and DEN IgM antibodies. 
Sera investigating on contacts of confirmed cases of dengue and yellow fever
Of the 185 sera from investigations tested in double detection for IgM anti-dengue virus and anti-yellow fever virus, 2 were positive for yellow fever IgM (1.08%), 3 were positive for dengue virus IgM, and 1 serum for dengue and yellow fever IgM (1.6%).
3.2. Detection of the viral genome and virus strain characterization Viral ARN detection by specific RT-PCR was performed on 182 early sera. Only one serum (from Sakassou, a district located in the center of the country) was positive for yellow fever on a negative IgM anti-yellow fever virus (Table 1) . For dengue, viral RNA was detected in 12 early sera (6.6%). Dengue virus typing carried by RT-PCR showed serotype 3 ( Table 2 ).
Epidemiological characteristics of confirmed cases of
yellow fever and dengue Regarding the immunization status of yellow fever confirmed cases, three had been vaccinated in 1999, 2000, and 2006. The age of the confirmed cases was between 5 and 48 years. More than 80% lived in Abidjan (Table 1) ; apart from the case from Anyama, a health district adjacent to Abidjan, the cases registered in the districts of Toumodi (Lakes region), Sakassou, and South Bouaké (Bandaman Valley Region) were located in the center of the country, and without any epidemiological link between them. Based on the date of onset of symptoms, the first three yellow fever confirmed cases occurred in April 2008 followed by 9 cases in June, 4 cases in July, 2 cases in August and September, and 1 case in October (Figure 1) .
The first two cases of dengue fever occurred in April 2008 followed by 4 cases in June, 24 cases in July, 1 case in August, and 2 cases in September (Figure 1 ). All dengue cases, except for one case from Adzopé (120 km from Abidjan), were residents of Abidjan health districts with more than 50% from Cocody-Bingerville (Table 2 ). The case from Adzopé had no epidemiological link to other cases. The age of viremic cases was between 8 and 55 years with 1.4 of the sex ratio. Clinically all yellow fever or dengue fever confirmed cases presented fever with jaundice, and only two dengue fever cases showed a hemorrhagic sign as hematuria. No death was reported in any of the cases.
Discussion
Yellow fever and dengue fever cases occurred in the second quarter of the year, at the beginning of the long rainy season with a peak in June for yellow fever and in July for dengue fever. This period favors the increase in population of YF and DEN vecors [3] .
Regarding age, adults aged 18 to 55 years old were most affected in both diseases, 85% for yellow fever and 93.7% for dengue fever, and some of the children affected were between 5 to 17 years old, a situation similar to earlier reports by Faye et al. (2003 Faye et al. ( -2004 ) who reported adults from 35 to 41 years old [8] . Yellow fever is endemic with recurrent outbreaks in Côte d'Ivoire [1] , however, this is the first report of dengue 3 infections in the country. Described in 1897 in Australia, several dengue fever cases or outbreaks including all serotypes have been reported in Africa since the 1980s after the first cases of dengue 1 and 2 reported in Nigeria by Carey et al. [2] and Fagbami et al. [7] : Southern Africa (South Africa, Mozambique) [11] , Eastern Africa (Kenya, Djibouti, Somalia) [17] , Central Africa (Cameroon) [12, 13] , and Western Africa (Senegal and Burkina Faso) [16] .
The first imported cases of dengue from Africa to Europe were described by Woodruff et al. in 1978 [20] . Apart from dengue 3 virus outbreak which occurred in Cape Verde affecting more than 16,000 persons including 6 deaths, concomitant of imported cases from Senegal to Italy [9] , dengue 3 was rarely reported in the West Africa subregion. Our findings pointed out Côte d'Ivoire as a dengue emerging country with DEN-3 virus, the serotype often associated with severe and hemorrhagic manifestations.
Among the confirmed dengue patients, two showed hemorrhagic signs in particular hematuria and 12 had expressed the viral RNA. All confirmed cases met the WHO standardized yellow fever suspected cases definition. This calls for a mandatory testing for dengue infection whenever there is a suspected YF case.
Considering the diagnosis aspects, using molecular diagnostic techniques has greatly improved the speed and accuracy of diagnosis of arboviruses as shown in Tables 1 and  2 . The immuno-enzymatic assay ELISA for specific IgM detection for arbovirus diagnosis is an undeniable contribution compared to viral isolation because it saves time during an epidemic situation; however IgM generally appears after 7 days of the date of onset of the disease and can cause a false negative result. In Table 1 , the case was found negative for IgM anti-yellow fever by ELISA but positive by RT-PCR. Virus or viral RNA presence in the first 5 or 7 days of the disease makes the molecular RT-PCR technique more sensitive than the ELISA at this period, as demonstrated in Table 2 . Indeed, the molecular test confirmed 7 dengue fever cases which were found negative by ELISA. The detection of viral antigens or viral RNA provided additional confirmation of the diagnosis. Molecular tools have become essential for their dual purpose: diagnosis and molecular characterization for determining genotypes and molecular epidemiology of the pathogen agents.
Conclusion
These results confirmed the existence of the two epidemics, yellow fever and dengue in Abidjan, which began in the second quarter of 2008, evolving simultaneously during the third quarter of 2008. They demonstrated the existence of different foci of transmission of these arboviruses in Côte d'Ivoire and the importance to add dengue fever on the list of diseases on epidemiological surveillance as yellow fever. The contribution of molecular tests revealed indispensable tools for the dengue fever cases detection and the genomic characterization of dengue virus strains.
